Artivion (AORT) Cash from Financing Activities (2010 - 2026)
Artivion (AORT) posted Cash from Financing Activities of $463000.0 for Q1 2026, down 80.95% on a QoQ basis from $2.4 million in Q4 2025, and down 88.24% year-over-year from $3.9 million in Q1 2025.
Artivion (AORT) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Artivion's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $463000.0 for Q1 2026.
- Quarterly Cash from Financing Activities fell 88.24% year-over-year to $463000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.8 million (up 44.51% YoY) and the FY2025 annual result came in at $11.3 million, up 412.12% from the prior year.
- Cash from Financing Activities was $463000.0 for Q1 2026 at Artivion, down from $2.4 million in the prior quarter.
- Across five years, Cash from Financing Activities topped out at $3.9 million in Q1 2025 and bottomed at -$1.6 million in Q4 2023.
- A 5-year average of $774941.2 and a median of $463000.0 in 2026 frame the typical range for Cash from Financing Activities.
- Annual changes were most pronounced in 2023 — Cash from Financing Activities plunged 460.71% — and 2025, when it surged 1535.36%.
- Artivion's Cash from Financing Activities stood at -$859000.0 in 2022, then sank by 89.76% to -$1.6 million in 2023, then surged by 110.67% to $174000.0 in 2024, then surged by 1296.55% to $2.4 million in 2025, then tumbled by 80.95% to $463000.0 in 2026.
- Business Quant data shows AORT's Cash from Financing Activities at $463000.0 in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Artivion | 1.25 Bn | 1.19 Bn | 75.45 Mn | 463,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 463,000.00 |
| Mar 31, 2026 | 463,000.00 |
| Dec 31, 2025 | 2.43 Mn |
| Dec 31, 2025 | 2.43 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Sep 30, 2025 | 2.32 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Jun 30, 2025 | 2.60 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Mar 31, 2025 | 3.94 Mn |
| Dec 31, 2024 | 174,000.00 |
| Dec 31, 2024 | 174,000.00 |
| Sep 30, 2024 | 1.47 Mn |
| Sep 30, 2024 | 1.47 Mn |
| Jun 30, 2024 | -181,000.00 |
| Jun 30, 2024 | -181,000.00 |
| Mar 31, 2024 | 737,000.00 |
| Mar 31, 2024 | 737,000.00 |
| Dec 31, 2023 | -1.63 Mn |
| Dec 31, 2023 | -1.63 Mn |